NCT04179045尚未招募不适用
A Registry Trial of the Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System in Patients With Coronary Artery Disease: BIOHEART Ⅲ
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 785
- 试验地点
- 5
- 主要终点
- TLF
研究概览
简要总结
This study is a prospective, multi-center single arm registry trial, planning to enroll 785 subjects. All subjects will receive clinical follow-up at 1 month, 6 month, 9 month and 1, 2, 3, 4, 5 year after index procedure. The primary endpoint will be target lesion failure (TLF) at 1 year after index procedure,which will be analyzed to evaluate the efficacy and safety of the device.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •General Inclusion Criteria:
- •Age from 18 to 75 years old, man or non-pregnant woman.
- •Subjects with asymptomatic ischemic evidence, stable or unstable angina, or old myocardial infarction, are suitable for selective PCI.
- •Subjects without contraindications of coronary artery bypass grafting (CABG).
- •Subjects are able to understand the purpose of this study, volunteer to participate and sign informed consent.
- •Angiographic Inclusion Criteria:
- •One or two de novo target lesions
- •If subject has only one target lesion, the second non-target lesion must be treated but the non-target lesion must be present in a different epicardial vessel; the non target lesion must be treated first and successfully prior to the subjects' register.
- •If there are two target lesions, they must be present in different epicardial vessels.
- •The definition of epicardial vessels means the left anterior descending artery (LAD), the left circumflex artery (LCX), and the right coronary artery (RCA) and their branches. Thus, for example, the subject must not have lesions requiring treatment in both the LAD and a branch.
- •Target lesion diameter stenosis is estimated visually ≥ 70% (or ≥ 50% with clinical evidence of myocardial ischemia), with TIMI flow grade ≥1; Target lesion length ≤24mm (visually); target lesion diameter between ≥2.5 mm to ≤ 4.00 mm.
- •Each target lesion must be covered completely by one scaffold.
排除标准
- •General Exclusion Criteria:
- •Any newly onset acute myocardial infarction within 1 week or, myocardial enzymes does not return to normal level after myocardial infarction.
- •Target vessel has been implanted with stents within 1 year before procedure.
- •Subjects with severe heart failure (≥ grade III NYHA) or left ventricular ejection fraction <35% (accessed by ultrasound or left ventricular angiography).
- •subject with severe kidney functional damaged before procedure: serum creatinine>2.0mg /dl (176.8μmol / L) or subject is receiving hemodialysis.
- •Subjects with high bleeding risk, with active gastrointestinal ulcers, history of cerebral hemorrhage or history of subarachnoid hemorrhage, history of ischemic stroke within the past six months, with contraindications of anti-platelet agents and anticoagulants, and subjects cannot receive antithrombolytic therapy.
- •subject is known hypersensitive or allergic to aspirin, clopidogrel, heparin, contrast agent, polylactic acid polymer and rapamycin.
- •The subject's life expectancy is less than 24 months.
- •Subjects is currently participating in other drug or medical device clinical trial that has not yet completed its primary endpoint .
- •Subjects have received any solid organ transplants or are ready to undergo organ transplant.
- •Subjects have unstable arrhythmia, such as high-risk ventricular premature beats, and ventricular tachycardia.
- •Subjects receive chemotherapy for tumor.
- •Subjects have received or planning to receive coronary or chest radiotherapy.
- •Subjects with Immunosuppressive, autoimmune diseases, have planned to receive or underwent immunosuppressive therapy.
- •Subjects have planned to receive or are receiving long-term anticoagulation therapy, such as heparin, warfarin and so on.
- •Subjects have planned to receive selective surgery within 6 months, which requires them to discontinue aspirin or clopidogrel.
- •Blood tests showed that the platelet count is less than 100 × 10^9 / L, or more than 700 × 10^9 / L, the white blood cells count is less than 3 × 10^9 /L.
- •subject with diagnosed or suspected liver cirrhosis.
- •Subjects with diffuse peripheral vascular disease, that precludes safe 6 French sheath insertion.
- •Angiographic exclusion criteria:
- •These exclusion criteria apply to the target or non-target lesion(s), target or non-target vessel(s):
- •Target or non-target lesion(s) located in left main.
- •Subjects with triple vessel lesion in LAD, LCX or RCA, which all need to be treated.
- •These exclusion criteria apply to the target lesion(s) or target vessel(s):
- •Target lesion located in left main.
- •Target lesion located in the aorto-ostial of RCA (within 3 mm of the origin of the RCA).
- •Target lesion located within 3 mm of the origin of the LAD and LCX.
- •Lesion involving a bifurcation with a:
- •Side branch ≥ 2.5 mm in diameter, or
- •Side branch with diameter stenosis ≥ 50%, or
- •Side branch requiring protection guide wire, or
- •Side branch requiring pre-dilatation.
- •Anatomy proximal to or within the lesion that may affect delivery of the Bioheart, including:
- •Extreme angulation (≥ 90°) proximal to or within the target lesion, or
- •Excessive tortuosity (≥ two 45° angles) proximal to or within the target lesion, or
- •Moderate or heavy calcification proximal to or within the target lesion.
- •Target lesion involves a myocardial bridge.
- •Target vessel contains thrombus as indicated in the angiographic images or IVUS.
- •Prior to the index procedure target vessel has been previously treated with a stent at any time such that the Bioheart stent would need to cross the stent to reach the target lesion.
- •Target vessel has been previously treated with a stent and the target lesion is within 5 mm proximal to a previously treated lesion.
- •Target lesion cannot meet the following outcomes, after the complete balloon pre-dilatation:
- •Residual (DS %) is < 40% (per visual estimation), ≤ 20% is strongly recommended;
- •TIMI Grade-3 flow (per visual estimation);
- •No angiographic complications (e.g., no-reflow, distal embolization, side branch closure)
- •No dissections NHLBI grade D-F;
- •No chest pain lasting > 5 minutes, and;
- •No ST depression or elevation lasting > 5 minutes.
结局指标
主要结局
TLF
时间窗: 1 year after index procedure
Target lesion failure, consists of cardiac death, MI attributed to the target vessel, and ischemic driven - target lesion revascularization (ID-TLR).
次要结局
- Lesion success(immediately after index procedure)
- The patient-oriented composite（PoCE）(at 1, 6, 9 month and 1, 2, 3, 4, 5 year after index procedure)
- Stent Thrombosis（ARC）(at 1, 6, 9 month and 1, 2, 3, 4, 5 year after index procedure)
- The device-oriented composite（DoCE） / TLF(at 1, 6, 9 month and 1, 2, 3, 4, 5 year after index procedure)
- Device success(immediately after index procedure)
- Clinical success(up to 7 days after index procedure)
研究者
研究点 (5)
Loading locations...
相似试验
Unknown
不适用
Effectiveness and Adherence of Golimumab in Rheumatoid ArthritisArthritis, RheumatoidNCT04188249Peking Union Medical College Hospital200
已完成
不适用
Nellix Registry Study: EVAS-GlobalAbdominal Aortic AneurysmNCT02996396Endologix48
尚未招募
2 期
Short-course Radiotherapy Combined With Furoquintinib and PD-1 Monoclonal AntibodyRectal CancerNCT06014944Changhai Hospital30
进行中（未招募）
不适用
ALPHA LONG Study- BioMatrix AlphaTM Stent Study in Patients With CADCoronary Artery DiseaseNCT05799963Biosensors Europe SA85
招募中
不适用
A Clinical Trial to Evaluate the Safety and Efficacy of IBS Angel in Patients With Pulmonary Artery StenosisPulmonary Artery StenosisNCT04973540Biotyx Medical (Shenzhen) Co., Ltd.82